Juana Hernández

Assisted reproductive technology in Europe, 2010: results generated from European registers by ESHRE

M. Kupka, Anna Pia Ferraretti, J. de Mouzon et al. · Human Reproduction · 2014 · 466 citations · Full text

Medicine, Gynecology, Assisted Reproductive Technologies +12

Assisted reproductive technology in Europe, 2013: results generated from European registers by ESHRE†

Carlos Calhaz–Jorge, Christian De Geyter, M. Kupka et al. · Human Reproduction · 2017 · 394 citations · Full text

Medicine, Gynecology, Obstetrics +15

Assisted reproductive technology in Europe, 2009: results generated from European registers by ESHRE†

Anna Pia Ferraretti, V. Goossens, M. Kupka et al. · Human Reproduction · 2013 · 380 citations · Full text

Veterinary Medicine, Gynecology, Assisted Reproductive Technologies +12

Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial

Bruno Coudert, Jean‐Yves Pierga, Marie‐Ange Mouret‐Reynier et al. · The Lancet Oncology · 2014 · 142 citations

Medicine, Oncology, Breast Oncology +15

Excision Repair Cross Complementation Group 1 Immunohistochemical Expression Predicts Objective Response and Cancer-Specific Survival in Patients Treated by Cisplatin-Based Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

Adriana Handra‐Luca, Juana Hernández, Giannis Mountzios et al. · Clinical Cancer Research · 2007 · 137 citations · Full text

Medicine, Cancer Biology, Oncology +13